Taisho Pharmaceutical Co., Ltd. is a Tokyo‐based multinational pharmaceutical company engaged in the research, development, manufacturing and marketing of both prescription and over‐the‐counter (OTC) healthcare products. The company operates through several business segments, including pharmaceuticals, quasi‐pharmaceuticals and food products. Its portfolio spans a wide range of therapeutic areas such as cardiovascular disease, central nervous system disorders, metabolism, oncology and immunology, complemented by a robust offering of consumer health products.
Among Taisho’s best‐known brands are Pabron, a leading OTC cold‐ and flu‐relief series sold primarily in Japan, and Lipovitan, one of the country’s first and most successful energy‐drink franchises. The company also holds rights to market and distribute internationally recognized brands under license, enhancing its consumer health lineup. On the prescription side, Taisho advances novel small‐molecule therapies and collaborates with global partners to develop treatments for diabetes, inflammation and other chronic conditions.
Founded in 1912, Taisho has grown from a domestic pharmaceutical producer to a global player with subsidiaries and joint ventures across Asia, North America and Europe. The company invests consistently in R&D, maintaining research facilities in Japan and overseas to support early‐stage discovery through late‐stage clinical development. Taisho’s global footprint is further strengthened by strategic alliances and targeted acquisitions, enabling it to bring both legacy and innovative products to markets worldwide.
AI Generated. May Contain Errors.
Free TAIPY Stock Alerts